Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Observational 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma, Large B-Cell, Diffuse 28Multiple Myeloma 26Lymphoma 26Lymphoma, Non-Hodgkin 21Leukemia, Myeloid, Acute 21Leukemia, Lymphocytic, Chronic, B-Cell 21Neoplasms 20Myelodysplastic Syndromes 19Lymphoma, Follicular 18Recurrence 16Lymphoma, B-Cell 16Leukemia 16Burkitt Lymphoma 16Lymphoma, Mantle-Cell 15Triple Negative Breast Neoplasms 14Ovarian Neoplasms 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Neuroblastoma 10Lymphoma, B-Cell, Marginal Zone 10Hodgkin Disease 10Sarcoma 8Melanoma 8Medulloblastoma 8Rhabdomyosarcoma 7Myeloproliferative Disorders 7Leukemia, Biphenotypic, Acute 7Carcinoma, Non-Small-Cell Lung 6Brain Neoplasms 6

Interventions

Vincristine 1Methotrexate 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1Cyclophosphamide 1Cisplatin 1Chemotherapy, Adjuvant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Ototoxicity × Cyclophosphamide × Clear all
NCT00683319 2013-09-20

Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy

National Cancer Institute (NCI)

Active not recruiting
50 enrolled
CNS

Ototoxicity, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡